| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | J Momand | |
| D Jung | |||
| J Niland | |||
| S Wilczynski | |||
| P2860 | cites work | Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain | Q24314763 |
| Isolation and identification of the human homolog of a new p53-binding protein, Mdmx | Q24318228 | ||
| ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways | Q24321528 | ||
| Mdm2 promotes the rapid degradation of p53 | Q24322597 | ||
| Mutation and cancer: statistical study of retinoblastoma | Q24618185 | ||
| Regulation of p53 stability by Mdm2 | Q27860744 | ||
| The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control | Q28259729 | ||
| Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53 | Q28260072 | ||
| The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 | Q28266637 | ||
| Amplification of a gene encoding a p53-associated protein in human sarcomas | Q28270924 | ||
| The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation | Q28280958 | ||
| Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line | Q28298821 | ||
| Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas | Q72657594 | ||
| A molecular study of EBV DNA and p53 mutations in nasopharyngeal carcinoma of Saudi Arab patients | Q72686877 | ||
| Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas | Q72769128 | ||
| MDM2 gene amplification in human breast cancer | Q72770396 | ||
| Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms | Q73158880 | ||
| p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate | Q73265770 | ||
| Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumours | Q73519484 | ||
| p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma | Q77555960 | ||
| The p53-mdm-2 autoregulatory feedback loop | Q28609811 | ||
| Cancer cell cycles | Q29547756 | ||
| The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 | Q29547773 | ||
| Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers | Q29616471 | ||
| mdm2 expression is induced by wild type p53 activity | Q29618316 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? | Q34232464 | ||
| Human papillomaviruses. | Q34316350 | ||
| Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors | Q34330309 | ||
| Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. | Q34399850 | ||
| Li-Fraumeni syndrome – a molecular and clinical review | Q34432117 | ||
| p53 and APC gene mutations: software and databases | Q34622913 | ||
| Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. | Q35643184 | ||
| Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage | Q35671727 | ||
| p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix | Q35833480 | ||
| Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line | Q35926080 | ||
| Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. | Q36080648 | ||
| Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. | Q36080896 | ||
| MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. | Q36081688 | ||
| DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours | Q36136448 | ||
| MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation | Q36431703 | ||
| The MDM2 oncoprotein binds specifically to RNA through its RING finger domain | Q36437940 | ||
| Alterations of the p53 gene in nasopharyngeal carcinoma | Q36698270 | ||
| p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family? | Q36831472 | ||
| An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma | Q37111674 | ||
| The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines | Q37537138 | ||
| The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis | Q38293411 | ||
| MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells | Q38343093 | ||
| Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. | Q38354926 | ||
| Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions | Q38475473 | ||
| Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. | Q38481936 | ||
| Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma | Q38510954 | ||
| Presence of p53 mutations in primary nasopharyngeal carcinoma (NPC) in non-Asians of Los Angeles, California, a low-risk population for NPC. | Q39449770 | ||
| Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis | Q40694250 | ||
| The molecular and genetic characterization of human soft tissue tumors. | Q40867777 | ||
| The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target | Q41024588 | ||
| Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. | Q41063629 | ||
| The mdm2 proto-oncogene | Q41100486 | ||
| Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas | Q41222000 | ||
| Mdm-2: "big brother" of p53. | Q41370313 | ||
| Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential | Q41451986 | ||
| Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas | Q41462464 | ||
| The mdm-2 oncogene is translocated and overexpressed in a murine plasmacytoma cell line expressing wild-type p53. | Q41470136 | ||
| Overexpression of the MDM2 oncogene in leukemia and lymphoma | Q41489317 | ||
| Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. | Q41511192 | ||
| Mdm2: keeping p53 under control | Q41585894 | ||
| MDM2--arbiter of p53's destruction | Q41633106 | ||
| Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome | Q41816411 | ||
| Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma | Q44949974 | ||
| MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma | Q44984040 | ||
| Mutations of the p53 gene are not detectable in human testicular tumors | Q46199216 | ||
| Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. | Q46716287 | ||
| Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein | Q48045977 | ||
| Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. | Q48115514 | ||
| Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms | Q48521959 | ||
| MDM2 and CDK4 gene amplification in Ewing's sarcoma | Q49180000 | ||
| Study of mdm2 gene amplification in primary breast tumors | Q49300699 | ||
| Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. | Q50751924 | ||
| Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. | Q52513658 | ||
| Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. | Q53484355 | ||
| Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. | Q53505421 | ||
| Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. | Q55478769 | ||
| p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. | Q55481604 | ||
| Analysis of glioma cell lines for amplification and overexpression of MDM2. | Q55481743 | ||
| mdm2 gene alterations and mdm2 protein expression in breast carcinomas | Q60609646 | ||
| Infrequent MDM2 gene amplification and absence of gross WAF1 gene alterations in nasopharyngeal carcinoma | Q60709858 | ||
| Over-expression of the MDM2 gene is found in some cases of haematological malignancies. | Q64922601 | ||
| MDM2 gene amplification in metastatic osteosarcoma | Q70521330 | ||
| p53 gene mutation in thyroid carcinoma | Q71046775 | ||
| p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas | Q71079486 | ||
| p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus | Q71512327 | ||
| Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors | Q71513567 | ||
| MDM2 gene amplification correlates with ring chromosome in soft tissue tumors | Q71636250 | ||
| mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations | Q71723499 | ||
| MDM2 gene amplification in bone and soft‐tissue tumors: Association with tumor progression in differentiated adipose‐tissue tumors | Q71820198 | ||
| A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma | Q71928758 | ||
| The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger | Q72100609 | ||
| Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma | Q72119630 | ||
| p53 alterations in uterine leiomyosarcomas versus leiomyomas | Q72134986 | ||
| MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status | Q72138136 | ||
| Altered patterns of MDM2 and TP53 expression in human bladder cancer | Q72138144 | ||
| MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas | Q72252451 | ||
| Lack of MDM2 amplification in human leukaemia | Q72490611 | ||
| The human MDM-2 oncogene is overexpressed in leukemias | Q72553957 | ||
| The p53 and mdm-2 genes in human testicular germ-cell tumors | Q72637768 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | database | Q8513 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 3453-3459 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | The MDM2 gene amplification database | |
| P478 | volume | 26 |
| Q42148989 | A Functional Polymorphism (rs937283) in the MDM2 Promoter Region is Associated with Poor Prognosis of Retinoblastoma in Chinese Han Population |
| Q33804888 | A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response. |
| Q64063524 | A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize |
| Q35691568 | A central role for the ring finger protein RNF11 in ubiquitin-mediated proteolysis via interactions with E2s and E3s. |
| Q40419093 | A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells |
| Q24336529 | A comprehensive framework of E2-RING E3 interactions of the human ubiquitin-proteasome system |
| Q38956062 | A fluorescent probe for imaging p53-MDM2 protein-protein interaction |
| Q33890625 | A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking |
| Q38797735 | A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin |
| Q73270818 | A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein |
| Q35029505 | A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation |
| Q24657532 | A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 |
| Q93197932 | A patent review of the ubiquitin ligase system: 2015-2018 |
| Q37168640 | A role for Numb in p53 stabilization |
| Q34770842 | A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene |
| Q79767255 | ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2 |
| Q37306546 | Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer |
| Q35094511 | Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis |
| Q53403786 | Absence of mutations in the functional domains of the human MDM2 oncogene in non-small cell lung carcinomas. |
| Q37543781 | Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation |
| Q33791305 | Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function. |
| Q42792438 | Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2 |
| Q41779296 | Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells |
| Q43053396 | Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine |
| Q34768629 | Alternative and aberrant splicing of MDM2 mRNA in human cancer |
| Q26784582 | Amplification of Cellular Oncogenes in Solid Tumors |
| Q37703117 | Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations |
| Q30320982 | Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma |
| Q77996259 | Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer |
| Q74332873 | An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2 |
| Q34754934 | An antibody-free strategy for screening putative HDM2 inhibitors using crude bacterial lysates expressing GST-HDM2 recombinant protein |
| Q24328822 | An essential function of the extreme C-terminus of MDM2 can be provided by MDMX |
| Q35552777 | An mTORC1-Mdm2-Drosha axis for miRNA biogenesis in response to glucose- and amino acid-deprivation |
| Q37736030 | Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas |
| Q36609221 | Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties |
| Q77053763 | Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas |
| Q42003660 | Anatomy of Mdm2 and Mdm4 in evolution. |
| Q26750639 | Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies |
| Q38854924 | Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays. |
| Q60961615 | Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis |
| Q47835390 | Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis. |
| Q46944917 | Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. |
| Q51775699 | Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. |
| Q35601228 | Association between positive murine double minute 2 expression and clinicopathological characteristics of esophageal squamous cell carcinoma: a meta-analysis |
| Q46489653 | Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer |
| Q28066326 | Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis |
| Q37317626 | Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate |
| Q35014385 | Awakening guardian angels: drugging the p53 pathway |
| Q35082715 | Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc |
| Q34080613 | Beta-peptides with improved affinity for hDM2 and hDMX. |
| Q41816238 | Binding induced folding in p53-MDM2 complex |
| Q52728031 | CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer. |
| Q34170979 | Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. |
| Q35082170 | Cell-cycle dysregulation and anticancer therapy |
| Q36998050 | Characterization of cancer-associated missense mutations in MDM2. |
| Q93195653 | Circ_0002770, acting as a competitive endogenous RNA, promotes proliferation and invasion by targeting miR-331-3p in melanoma |
| Q77856954 | Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma |
| Q73644143 | Cloning, sequence analysis and expression of the cDNAs encoding the canine and equine homologues of the mouse double minute 2 (mdm2) proto-oncogene |
| Q28386766 | Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore |
| Q33633277 | Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy |
| Q34396047 | Combining targeted agents with modern radiotherapy in soft tissue sarcomas |
| Q87603523 | Comparison of Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization for the Evaluation of MDM2 Amplification in Adipocytic Tumors |
| Q35942016 | Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis |
| Q36216371 | Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction. |
| Q58766015 | Contribution of Murine Double Minute 2 Genotypes to Colorectal Cancer Risk in Taiwan |
| Q40842578 | Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2. |
| Q34761024 | Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. |
| Q38739726 | Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation |
| Q57764814 | Correlation between the Expression Level of the MDM Homolog Gene and Inflammatory Lesions in Different Populations of the Model Organism Mytilus Galloprovincialis from Polluted Areas of the Gulf of Naples (Southern Italy) |
| Q39242233 | Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma |
| Q24297332 | Critical role for Daxx in regulating Mdm2 |
| Q47864973 | Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk |
| Q90535533 | Cytohistological correlation, immunohistochemistry and Murine Double Minute Clone 2 amplification of pulmonary artery intimal sarcoma: A case report with review of literature |
| Q44386340 | DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer |
| Q36871609 | Dangerous habits of a security guard: the two faces of p53 as a drug target |
| Q24299167 | Daxx is reciprocally regulated by Mdm2 and Hausp |
| Q34515307 | Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases |
| Q34700590 | Defective osteogenic differentiation in the development of osteosarcoma |
| Q40626844 | Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification |
| Q42099865 | Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles. |
| Q28548694 | Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction |
| Q27003153 | Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1 |
| Q81596434 | Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects |
| Q35044801 | Development of inhibitors in the ubiquitination cascade |
| Q39294214 | Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. |
| Q36144233 | Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment |
| Q37283483 | Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53. |
| Q33789802 | Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy |
| Q64970972 | Dissecting the role of RNA modification regulatory proteins in melanoma. |
| Q75208909 | Distinct MDM2 and P14ARF expression and centrosome amplification in well-differentiated liposarcomas |
| Q40068515 | Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates |
| Q38191796 | Drugging the p53 pathway: understanding the route to clinical efficacy |
| Q36558129 | Drugs targeting protein-protein interactions |
| Q34139691 | Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities |
| Q28086796 | Dysregulation of ubiquitin ligases in cancer |
| Q35082710 | E3 ubiquitin ligases as cancer targets and biomarkers |
| Q39560187 | Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma |
| Q33403930 | Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study |
| Q35693755 | Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk |
| Q37167981 | Enhancing radiosensitivity of TE1, TE8, and TE 11 esophageal squamous carcinoma cell lines by Hdm2-siRNA targeted gene therapy in vitro |
| Q34360157 | Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice |
| Q58860198 | Environment-sensitive turn-on fluorescent probes for p53-MDM2 protein-protein interaction |
| Q39879529 | Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. |
| Q37702737 | Estradiol shows anti-skin cancer activities through decreasing MDM2 expression |
| Q39317652 | Evaluation and Elucidation Studies of Natural Aglycones for Anticancer Potential using Apoptosis-Related Markers: An In silico Study |
| Q39593069 | Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. |
| Q52746431 | Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. |
| Q60303014 | Exploiting Oncogenic Drivers along the Pathway for Cancer Therapy and Gene Therapy |
| Q24300022 | Expression of the Bcl-3 proto-oncogene suppresses p53 activation |
| Q37736196 | FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2. |
| Q40311468 | GC-selective DNA-binding antibiotic, mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis. |
| Q34146539 | Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway. |
| Q53399243 | Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma. |
| Q36115735 | Genetic changes in squamous cell lung cancer: a review |
| Q53352506 | Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. |
| Q33557871 | Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population |
| Q35311763 | Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA. |
| Q90746246 | Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells |
| Q26746946 | HCV-Induced Oxidative Stress: Battlefield-Winning Strategy |
| Q24338503 | HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function |
| Q39871502 | Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage |
| Q35795406 | Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin. |
| Q41287827 | High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas |
| Q42427815 | Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling |
| Q40343248 | Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control |
| Q35641639 | Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops |
| Q57350991 | Hydrocarbon-Stapled Helices: A Novel Approach for Blocking Protein-Protein Interactions |
| Q92215465 | IGFBP-2 in cervical cancer development |
| Q28565709 | Identification and characterization of a novel Mdm2 splice variant acutely induced by the chemotherapeutic agents adriamycin and actinomycin D |
| Q24315623 | Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains |
| Q36252658 | Identification of FDA-approved drugs that computationally bind to MDM2 |
| Q34218811 | Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice |
| Q36405382 | Identification of functional DNA variants in the constitutive promoter region of MDM2 |
| Q35057299 | Identification of novel rab27a/melanophilin blockers by pharmacophore-based virtual screening |
| Q38904655 | Identifying the determinants of response to MDM2 inhibition. |
| Q49859661 | Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers |
| Q35161409 | Immunohistochemistry in the diagnosis of soft tissue tumours |
| Q45947620 | Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. |
| Q54527845 | Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma. |
| Q36348947 | Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells |
| Q28505083 | Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions |
| Q37275707 | In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction |
| Q33963311 | Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. |
| Q42152329 | Inactivation of the p53 pathway in retinoblastoma. |
| Q36149306 | Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth |
| Q39022440 | Induction of p53 suppresses chronic myeloid leukemia. |
| Q45859705 | Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon |
| Q35058579 | Inhibiting the p53-MDM2 interaction: an important target for cancer therapy |
| Q36040768 | Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma |
| Q47251018 | Inhibition of MDM2 by a rhein-derived compound AQ-101 suppresses cancer development in SCID mice. |
| Q35195759 | Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia |
| Q35232862 | Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival |
| Q34170586 | Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer c |
| Q91923645 | Inhibition of p53 inhibitors: progress, challenges and perspectives |
| Q36957764 | Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma |
| Q37855826 | Inhibitors of MDM2 and MDMX: a structural perspective. |
| Q37480094 | Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells. |
| Q33656086 | Interplay between Mdm2 and HIPK2 in the DNA damage response |
| Q49629601 | Inverse association between MDM2 and HUWE1 protein expression levels in human breast cancer and liposarcoma |
| Q39989774 | Isoquinolin-1-one inhibitors of the MDM2-p53 interaction |
| Q36423924 | Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. |
| Q41080806 | Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner |
| Q42511030 | Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance |
| Q80827612 | Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development |
| Q41701656 | Low dose arsenite confers resistance to UV induced apoptosis via p53-MDM2 pathway in ketatinocytes |
| Q91845144 | MDM2 Inhibition in a Subset of Sarcoma Cell Lines Increases Susceptibility to Radiation Therapy by Inducing Senescence in the Polyploid Cells |
| Q37872630 | MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis |
| Q83449378 | MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone |
| Q33915624 | MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines |
| Q40013409 | MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. |
| Q91755518 | MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388) |
| Q35848425 | MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy |
| Q38442004 | MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. |
| Q39812610 | MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option? |
| Q54428508 | MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis. |
| Q34489720 | MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. |
| Q97531386 | MDM2 inhibition: an important step forward in cancer therapy |
| Q39584251 | MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon |
| Q37688946 | MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. |
| Q51743355 | MDM2 is overexpressed and regulated by the eukaryotic translation initiation factor 4E (eIF4E) in human squamous cell carcinoma of esophagus. |
| Q24793105 | MDM2 negatively regulates the human telomerase RNA gene promoter |
| Q34257381 | MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk |
| Q37254339 | MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer |
| Q36270358 | MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk |
| Q35071303 | MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation |
| Q91997757 | MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1 |
| Q33897779 | MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change |
| Q35599095 | MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia |
| Q73739357 | MDM2 sensitizes a human ovarian cancer cell line |
| Q28138926 | MDM2--master regulator of the p53 tumor suppressor protein |
| Q33869257 | MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer |
| Q38073178 | MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas |
| Q34999483 | MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. |
| Q37465881 | Mathematical model of dynamic protein interactions regulating p53 protein stability for tumor suppression |
| Q38059700 | Mdm2 and MdmX as Regulators of Gene Expression |
| Q41287457 | Mdm2 and tumorigenesis: evolving theories and unsolved mysteries |
| Q37268813 | Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo |
| Q39738242 | Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis |
| Q36294472 | Mdm2 in growth signaling and cancer |
| Q41337111 | Mdm2 promotes genetic instability and transformation independent of p53. |
| Q50899909 | Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53. |
| Q53413644 | Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin. |
| Q83855443 | Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death |
| Q35572466 | Mdm2: A regulator of cell growth and death |
| Q33594040 | Mdm2: the ups and downs |
| Q28210052 | MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination |
| Q39404029 | MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress |
| Q42546083 | Mdmx promotes genomic instability independent of p53 and Mdm2. |
| Q39629766 | Melatonin and vitamin D3 synergistically down‐regulate Akt and MDM2 leading to TGFβ‐1‐dependent growth inhibition of breast cancer cells |
| Q47963325 | MiR-641 Functions as a Tumor Suppressor by Targeting MDM2 in Human Lung Cancer |
| Q34619254 | MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling |
| Q26784033 | MicroRNAs and Potential Targets in Osteosarcoma: Review |
| Q74577766 | Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma |
| Q45888472 | Mild hyperthermia plus adenoviral p53 over-expression additively inhibits the viability of human malignant glioma cells |
| Q35679203 | Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction |
| Q26775356 | Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics |
| Q33621929 | Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions |
| Q55100479 | Molecular analysis of oncogenes, ras family genes (N-ras, K-ras, H-ras), myc family genes (c-myc, N-myc) and mdm2 in natural killer cell neoplasms. |
| Q40772738 | Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms |
| Q35746191 | Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia |
| Q38588243 | Molecular basis of differentiation therapy for soft tissue sarcomas |
| Q45874458 | Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation |
| Q39793825 | Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort |
| Q34516626 | Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. |
| Q37183461 | Molecular pathology and potential therapeutic targets in soft-tissue sarcoma |
| Q36436702 | Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo |
| Q40200606 | Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. |
| Q38074740 | Mouse models of Mdm2 and Mdm4 and their clinical implications |
| Q38083248 | Multiple carcinosarcomas of the esophagus and stomach |
| Q28207477 | Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2 |
| Q37149486 | Multivalency-assisted control of intracellular signaling pathways: application for ubiquitin- dependent N-end rule pathway |
| Q35930829 | Murine Double-Minute 2 Homolog Single Nucleotide Polymorphisms 285 and 309 in Cervical Carcinogenesis. |
| Q34978872 | Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression |
| Q34245527 | Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence. |
| Q36636154 | NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2. |
| Q28392562 | NT4(Si)-p53(N15)-antennapedia induces cell death in a human hepatocellular carcinoma cell line |
| Q57496075 | Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine |
| Q36084467 | Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy |
| Q26774960 | Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis |
| Q35939102 | Novel activators of the tumour suppressor p53. |
| Q35011473 | Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. |
| Q40271670 | Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. |
| Q38656647 | Nutlin-3, A P53-Mdm2 Antagonist For Nasopharyngeal Carcinoma Treatment |
| Q38710594 | Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53. |
| Q39718188 | Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells |
| Q35146560 | Oncogenes in melanoma |
| Q36803600 | Osteosarcoma development and stem cell differentiation |
| Q53414752 | P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival. |
| Q34723518 | PAK1IP1, a ribosomal stress-induced nucleolar protein, regulates cell proliferation via the p53-MDM2 loop. |
| Q44848220 | PTEN regulates Mdm2 expression through the P1 promoter |
| Q92405554 | Pan-Cancer and Single-Cell Modeling of Genomic Alterations Through Gene Expression |
| Q37580429 | Panels of tumor-derived RNA markers in peripheral blood of patients with non-small cell lung cancer: their dependence on age, gender and clinical stages |
| Q35852309 | Pathways of apoptotic and non-apoptotic death in tumour cells |
| Q37262594 | Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction. |
| Q37317259 | Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway |
| Q35559055 | Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases |
| Q24313228 | Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding |
| Q39785618 | Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor |
| Q24298615 | Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1 |
| Q39612489 | Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells |
| Q52680895 | Predictive gene signatures determine tumor sensitivity to MDM2 inhibition. |
| Q34939959 | Proteasome inhibitors in cancer therapy |
| Q41287206 | Protecting the genome from mdm2 and mdmx |
| Q34478822 | Protein-protein interactions for cancer therapy |
| Q35492010 | Proteomic signatures associated with p53 mutational status in lung adenocarcinoma |
| Q30665587 | QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction |
| Q35927931 | Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation |
| Q24297569 | RBB, a novel transcription repressor, represses the transcription of HDM2 oncogene |
| Q74355214 | RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome |
| Q34093164 | RNA polymerase III transcription: its control by tumor suppressors and its deregulation by transforming agents |
| Q36028214 | RNA polymerases I and III, growth control and cancer |
| Q30419679 | Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy |
| Q34646656 | Recent advances in cancer research: mouse models of tumorigenesis |
| Q29615658 | Regulating the p53 pathway: in vitro hypotheses, in vivo veritas |
| Q36935206 | Regulation of hormone signaling by nuclear receptor interacting proteins |
| Q28510160 | Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage |
| Q35108767 | Regulation of p53 level by UBE4B in breast cancer |
| Q35161624 | Regulation of the DNA damage response by ubiquitin conjugation |
| Q24681793 | Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism |
| Q48319353 | Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7. |
| Q92443905 | Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway |
| Q46738656 | Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression |
| Q27006998 | Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53 |
| Q38789263 | Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q37818291 | Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy |
| Q34850281 | Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network |
| Q34085616 | Role of Pirh2 in mediating the regulation of p53 and c-Myc |
| Q58884817 | Roles for negative cell regulator 14-3-3σ in control of MDM2 activities |
| Q33781079 | Roles of E3 ubiquitin ligases in cell adhesion and migration |
| Q36642763 | SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. |
| Q34584722 | SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression |
| Q92355364 | SCFFBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis |
| Q39555703 | SMG7 is a critical regulator of p53 stability and function in DNA damage stress response. |
| Q35751762 | SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers |
| Q35017038 | Screening E3 substrates using a live phage display library |
| Q34003810 | Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2. |
| Q37806669 | Small-Molecule Inhibitors of the p53-MDM2 Interaction |
| Q34478557 | Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy |
| Q35087851 | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. |
| Q24651380 | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy |
| Q22010970 | Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein |
| Q39492626 | Stochastic and Deterministic Models of Cellular p53 Regulation. |
| Q34579681 | Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers |
| Q78353663 | Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells |
| Q34627210 | Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers |
| Q42775571 | Synthesis of a Macrocycle Based on Linked Amino Acid Mimetics (LAAM). |
| Q36623678 | TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe |
| Q34568607 | TP53: a key gene in human cancer. |
| Q39548243 | Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy |
| Q24814753 | Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer |
| Q35030217 | Targeting MDM2-p53 interaction for cancer therapy: are we there yet? |
| Q92134663 | Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia |
| Q33655329 | Targeting p53 for Novel Anticancer Therapy |
| Q38749151 | Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. |
| Q37177586 | Targeting the MDM2-p53 interaction for cancer therapy |
| Q41303735 | Targeting the p53 Pathway in Ewing Sarcoma. |
| Q35903526 | Targeting the p53-MDM2 interaction to treat cancer |
| Q38059739 | Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy |
| Q90069521 | Targeting transcription factors in cancer - from undruggable to reality |
| Q36986557 | Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. |
| Q35624079 | The 26S proteasome complex: an attractive target for cancer therapy |
| Q90138220 | The 40bp indel polymorphism of MDM2 increase the risk of cancer: An updated meta-analysis |
| Q36514299 | The Current and Future Therapies for Human Osteosarcoma |
| Q38802685 | The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα. |
| Q38606962 | The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells |
| Q34460686 | The MDM2 gene family |
| Q38858580 | The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer |
| Q37039474 | The MDM2-p53 pathway revisited |
| Q36387610 | The Regulation of Multiple p53 Stress Responses is Mediated through MDM2 |
| Q38837916 | The Role of MDM2 Amplification and Overexpression in Tumorigenesis |
| Q47096280 | The Role of MDM2 in Promoting Genome Stability versus Instability. |
| Q55517350 | The Roles of MDM2 and MDMX in Cancer. |
| Q24297633 | The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop |
| Q36766027 | The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells |
| Q38192005 | The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins |
| Q27006931 | The emerging roles of ribosome biogenesis in craniofacial development |
| Q38262432 | The evolution of MDM2 family genes |
| Q51803160 | The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC). |
| Q37483795 | The functioning antigens: beyond just as the immunological targets |
| Q42553290 | The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival |
| Q48287375 | The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. |
| Q73673966 | The loss of mdm2 induces p53-mediated apoptosis |
| Q91289449 | The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways |
| Q38901084 | The overexpression of SOX2 affects the migration of human teratocarcinoma cell line NT2/D1. |
| Q27690770 | The p53 pathway as a target in cancer therapeutics: obstacles and promise |
| Q36161258 | The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability |
| Q37599707 | The regulation of MDM2 oncogene and its impact on human cancers |
| Q40784946 | The regulation of the p53/MDM2 feedback loop by microRNAs |
| Q28072553 | The role of p53 in cancer drug resistance and targeted chemotherapy |
| Q33792857 | The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA. |
| Q27685287 | The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant |
| Q36617172 | The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. |
| Q36879301 | Therapeutic targets in the ARF tumor suppressor pathway. |
| Q24536285 | Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation |
| Q24537716 | Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes |
| Q35708113 | Translational approaches targeting the p53 pathway for anti-cancer therapy |
| Q28082910 | Trial Watch: Proteasomal inhibitors for anticancer therapy |
| Q37269178 | Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer |
| Q36605006 | Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway |
| Q33930350 | Tumor suppressors and oncogenes in cellular senescence. |
| Q45864999 | Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53. |
| Q35082705 | Ubiquitin and ubiquitin-like modifications of the p53 family |
| Q34503492 | Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets |
| Q36946774 | Ubiquitin ligases in cancer: ushers for degradation |
| Q39606430 | Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy |
| Q35186715 | Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors |
| Q38059699 | Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis |
| Q37748214 | Using mice to examine p53 functions in cancer, aging, and longevity |
| Q24599716 | Visualization and targeted disruption of protein interactions in living cells |
| Q34662167 | WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells |
| Q42058130 | Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo |
| Q42466219 | Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene |
| Q38266298 | Wip1 phosphatase in breast cancer |
| Q35673760 | Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents |
| Q38065264 | YB-1: oncoprotein, prognostic marker and therapeutic target? |
| Q37649231 | YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway. |
| Q40015788 | hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells |
| Q36962411 | microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis. |
| Q36387615 | p53 Regulation Goes Live-Mdm2 and MdmX Co-Star: Lessons Learned from Mouse Modeling |
| Q42034071 | p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer |
| Q28483922 | p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors |
| Q51304816 | p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. |
| Q46251110 | p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a |
| Q29619502 | p53 ubiquitination: Mdm2 and beyond |
| Q38247164 | p53-independent effects of Mdm2. |
| Q36935974 | p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours |
| Q45888635 | p53: balancing tumour suppression and implications for the clinic |
Search more.